159 related articles for article (PubMed ID: 37977000)
1. Prognosticators of survival in patients with metastatic pancreatic cancer and ascites.
Berger JM; Alany A; Berchtold L; Puhr R; Friedrich A; Scheiner B; Prager GW; Preusser M; Berghoff AS; Bergen ES
ESMO Open; 2023 Dec; 8(6):102048. PubMed ID: 37977000
[TBL] [Abstract][Full Text] [Related]
2. Clinical risk factors for ascites in metastatic pancreatic cancer.
Berger JM; Alany A; Puhr R; Berchtold L; Friedrich A; Scheiner B; Prager GW; Berghoff AS; Preusser M; Bergen ES
ESMO Open; 2023 Apr; 8(2):101200. PubMed ID: 36989885
[TBL] [Abstract][Full Text] [Related]
3. Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA.
DeWitt J; Yu M; Al-Haddad MA; Sherman S; McHenry L; Leblanc JK
Gastrointest Endosc; 2010 Feb; 71(2):260-5. PubMed ID: 19922924
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
5. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
[TBL] [Abstract][Full Text] [Related]
6. Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases.
Ouyang H; Ma W; Zhang T; Liu F; Zhao L; Fang M; Quan M; Pan Z
Pancreatology; 2018 Dec; 18(8):983-989. PubMed ID: 30287168
[TBL] [Abstract][Full Text] [Related]
7. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience.
Vijayvergia N; Dotan E; Devarajan K; Hatahet K; Rahman F; Ricco J; Lewis B; Gupta S; Cohen SJ
J Geriatr Oncol; 2015 Nov; 6(6):454-61. PubMed ID: 26296909
[TBL] [Abstract][Full Text] [Related]
8. Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy.
Deutsch GB; Flaherty DC; Kirchoff DD; Bailey M; Vitug S; Foshag LJ; Faries MB; Bilchik AJ
JAMA Surg; 2017 Jul; 152(7):672-678. PubMed ID: 28384791
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis.
Alberghina N; Sánchez-Montes C; Tuñón C; Maurel J; Araujo IK; Ferrer J; Sendino O; Córdova H; Vaquero EC; González-Suárez B; Martínez-Palli G; Ginès À; Fernández-Esparrach G
Pancreatology; 2017; 17(5):858-864. PubMed ID: 28844696
[TBL] [Abstract][Full Text] [Related]
10. Impact of carcinomatosis and ascites status on long-term outcomes of palliative treatment for patients with gastric outlet obstruction caused by unresectable gastric cancer: stent placement versus palliative gastrojejunostomy.
Park CH; Park JC; Kim EH; Chung H; An JY; Kim HI; Shin SK; Lee SK; Cheong JH; Hyung WJ; Lee YC; Noh SH; Kim CB
Gastrointest Endosc; 2015 Feb; 81(2):321-32. PubMed ID: 25085332
[TBL] [Abstract][Full Text] [Related]
11. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
[TBL] [Abstract][Full Text] [Related]
12. Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.
Gbolahan O; Hashemi-Sadraei N; Yash S; Williams G; Ramachandran R; Kim YI; Paluri R; Outlaw D; El-Rayes B; Nabell L
Cancer Med; 2023 Feb; 12(3):3488-3498. PubMed ID: 35979540
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer with malignant ascites: clinical features and outcomes.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Hamada T; Mizuno S; Miyabayashi K; Mohri D; Kogure H; Matsubara S; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Pancreas; 2015 Apr; 44(3):380-5. PubMed ID: 25636085
[TBL] [Abstract][Full Text] [Related]
14. Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis.
Sun T; Li K; Xu G; Zhu K; Wang Q; Dang C; Yuan D
World J Surg Oncol; 2021 Jul; 19(1):200. PubMed ID: 34229721
[TBL] [Abstract][Full Text] [Related]
15. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
16. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors.
Chu DZ; Lang NP; Thompson C; Osteen PK; Westbrook KC
Cancer; 1989 Jan; 63(2):364-7. PubMed ID: 2910444
[TBL] [Abstract][Full Text] [Related]
18. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Vienot A; Beinse G; Louvet C; de Mestier L; Meurisse A; Fein F; Heyd B; Cleau D; d'Engremont C; Dupont-Gossart AC; Lakkis Z; Tournigand C; Bouché O; Rousseau B; Neuzillet C; Bonnetain F; Borg C; Vernerey D
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383673
[TBL] [Abstract][Full Text] [Related]
19. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Al-Batran SE; Hofheinz RD; Reichart A; Pauligk C; Schönherr C; Schlag R; Siegler G; Dörfel S; Koenigsmann M; Zahn MO; Schubert J; Aldaoud A; Höffkes HG; Schulz H; Hahn L; Uhlig J; Blau W; Stauch M; Weniger J; Wolf M; Jacobasch L; Bildat S; Wehmeyer J; Homann N; Trojan J; Waidmann O; Fietz T; Feustel HP; Groschek M; Wierecky J; Waibel K; Mahlmann S; Schwindel U; Peters U; Schuch G; Pink D; Eschenburg H; Wörns MA; Harich HD; von Weikersthal LF; Däßler KU; Behringer DM; Messmann H; Kretzschmar A; Gallmeier E; Forstbauer H; Kunzmann V; Papke J; Büchner-Steudel P; Vehling-Kaiser U; Springfeld C; Vogel A; Ettrich TJ; Schaaf M; Hausen GZ; Götze TO;
Int J Cancer; 2021 Mar; 148(6):1478-1488. PubMed ID: 33038277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
